

0001213900-25-0012416-K PURPLE BIOTECH LTD. 2025010620250106172602172603172603 0 0001213900-25-0012416-K 1 20250106 20250106 20250106 PURPLE BIOTECH LTD. 0001614744 2834 000000000 L3 1231 6-K 34 001-37643 25512437 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 97239333121 4 OPPENHEIMER STREET SCIENCE PARK REHOVOT L3 7670104 Kitov Pharma Ltd. 20180125 Kitov Pharmaceuticals Holdings Ltd. 20140724 6-K 1 ea0226945-6k\_purplebio.htm REPORT OF FOREIGN PRIVATE ISSUER Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.Â 20549 Â FORM 6-K Â Â Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 ofÂ the Securities Exchange Act of 1934 Â For the month of January 2025 Commission File Number: 001-37643 Â PURPLE BIOTECH LTD. (Translation of registrantâ€™s name into English) Â 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal executive offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.Â Â Form 20-F Â~Â Â Form 40-F Â~Â Â Â Â As previously disclosed, on June 9, 2021, Purple Biotech Ltd. (the â€œCompanyâ€) entered into an Open Market Sale AgreementSM (the â€œATM Agreementâ€) with Jefferies LLC (the â€œAgentâ€), as sales agent, pursuant to which the Company may offer and sell American Depository Shares (the â€œADSsâ€), with each ADS representing two hundred of the Companyâ€™s ordinary shares (the â€œSharesâ€), from time to time in an â€œat the market offeringâ€ program. Â The ADSs will be offered and sold pursuant to a sales agreement prospectus, dated May 22, 2023, forming a part of the Companyâ€™s registration statement on Form F-3, as amended (File No. 333-268710), initially filed with the Securities and Exchange Commission on December 7, 2022 and declared effective on May 22, 2023, as supplemented by the prospectus supplements, dated October 17, 2023 and January 6, 2025. The initial sales agreement prospectus registered the offer and sale of up to \$12.0 million of Shares. The prospectus supplement filed on October 17, 2023 reduced the amount of Shares available to be sold pursuant to the ATM Agreement to \$3.0 million of Shares. As of the date hereof, the Company has sold an aggregate of approximately \$4.0 million of Shares under the initial sales agreement prospectus effective on May 22, 2023 and the prospectus supplement filed on October 17, 2023. On January 6, 2025, the Company determined to increase the amount available for sale under the ATM Agreement, up to an additional aggregate offering price of \$1,330,000, from and after the date hereof. Â Because there is no minimum offering amount required pursuant to the ATM Agreement, the total number of ADSs to be sold under the ATM Agreement, if any, and proceeds to the Company, if any, are not determinable at this time. The Company expects to use any net proceeds primarily for working capital and general corporate purposes. The Company has not yet determined the amount of net proceeds to be used specifically for any particular purpose or the timing of these expenditures. Accordingly, the Companyâ€™s management will have significant discretion and flexibility in applying the net proceeds from the sale of these securities, if any. Â A copy of the opinion of ABZ Law Office relating to the validity of the Shares underlying the ADSs that may be sold pursuant to the ATM Agreement and a copy of the opinion of Haynes and Boone, LLP relating to the validity of the ADSs that may be sold pursuant to the ATM Agreement were filed with the Companyâ€™s registration statement on Form F-3, as amended (File No. 333-268710). Â This Report on Form 6-K, including the exhibits filed herewith, shall not constitute an offer to sell or the solicitation of an offer to buy the ADSs that may be sold pursuant to the ATM Agreement, nor shall there be any offer, solicitation or sale of the ADSs in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country. Â Incorporation by Reference Â This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrantâ€™s Registration Statement onÂ Form S-8Â filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrantâ€™s Registration Statement onÂ Form S-8Â filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrantâ€™s Registration Statement onÂ Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrantâ€™s Registration Statement onÂ Form S-8Â filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrantâ€™s Registration Statement onÂ Form F-3Â filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrantâ€™s Registration Statement onÂ Form F-1Â filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrantâ€™s Registration Statement onÂ Form F-3Â filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrantâ€™s Registration Statement onÂ Form S-8Â filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrantâ€™s Registration Statements onÂ Form F-3Â filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrantâ€™s Registration Statement onÂ Form S-8Â filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrantâ€™s Registration Statement onÂ Form F-3Â filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrantâ€™s Registration Statement onÂ Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), the Registrantâ€™s Registration Statement onÂ Form F-1,Â as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrantâ€™s Registration Statement onÂ Form F-1,Â filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Â 1 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â January 6, 2025 PURPLE BIOTECH LTD. Â Â Â By: /s/ Gil Efron Â Â Gil Efron Â Â Chief Executive Officer Â Â 2 Â Â